Locus is developing powerful, precision medicines designed to combat the growing antimicrobial resistance (AMR) pandemic and treat diseases of the microbiome.
Worldwide, an estimated 150 million people are affected by UTIs each year. The high prevalence of E. coli (80%), high rate of recurrence (40%), and growing rate of antimicrobial resistance to commonly used antibiotics (>25%) epitomizes the growing need for patients experiencing these infections. LBP-EC01 is engineered to meet these needs.
In 2019 Antimicrobial Resistance (AMR) was directly responsible for >1.2 million deaths. Since the COVID-19 pandemic, misuse and overuse of antibiotics coupled with overrun healthcare systems have sent infection and resistance rates skyrocketing. The Locus Biopharmaceutical Development platform was purpose built to take this challenge head-on.
We are on a mission to revolutionize the treatment of disease. We need intelligent, open, hard-working people who thrive in a fast-paced environment to join us on our quest.
A collection of all the microbes that live on or in the human body, the microbiome plays an important role in your health. Day-to-day your microbiome helps digest your food, produce vitamins, regulate your immune system, and protect against other microbes that cause disease.
When the balance is disrupted, problematic microbes can take hold and cause or exacerbate:
Locus Biosciences has built the world’s most powerful platform to selectively remove pathogenic bacterial species from the human body while leaving the many species of “good” bacteria in the microbiome unaffected. Our products can also exploit bacteria in the microbiome to produce therapeutics that may be beneficial in treating a variety of diseases.
Locus Biosciences has built a world-class biologics manufacturing facility—recognized by the International Society for Pharmaceutical Engineering (ISPE) in 2021 with its prestigious “Facility of the Year” award—to enable GMP manufacturing of its precision therapeutics.
LBP-EC01 is a precision therapeutic designed to target E. coli infections. More specifically, it is a cocktail of bacteriophages engineered to precisely remove E. coli in patients with urinary tract infections (UTIs).
LBP-PA01 is a precision therapeutic designed to target P. aeruginosa infections. Locus has partnered with Janssen Pharmaceuticals to develop this product.
LBP-SA01 is a precision therapeutic designed to target S. aureus infections. Locus has partnered with Janssen Pharmaceuticals to develop this product.
LBP-KP01 is a precision therapeutic designed to target K. pneumoniae infections. Locus has partnered with the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to develop this product.
Locus Biosciences is developing multiple approaches leveraging its Locus Biopharmaceutical Development platform to address both the pathogens and the resulting damage associated with Inflammatory Bowel Disease.
Locus Biosciences is a precision medicine company that is developing bacteriophage-based products to precisely remove pathogenic bacteria from the human body and to leverage the microbiome to treat diseases across multiple therapeutic areas.
We are supported by an exceptional team of partners across academia,
government, large pharma, and investors.